Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- A8703 IsosafroleTarget: Lactate Dehydrogenases (LDH)Summary: A stiripentol analog, a potent LDH inhibitor.
- A4015 DisulfiramTarget: Aldehyde DehydrogenasesSummary: Dopamine β-hydroxylase inhibitor
- A4056 AT13387Target: HSP90Summary: Hsp90 inhibitor
- A4057 AUY922 (NVP-AUY922)1 CitationTarget: HSP90Summary: Potent Hsp90 inhibitor
- A4060 Geldanamycin2 CitationSummary: Hsp90 inhibitor,potent and specific
- A4061 IPI-504 (Retaspimycin hydrochloride)3 CitationTarget: HSP90Summary: Hsp90 inhibitor,novel, potent,selective
- A4064 NVP-BEP800Target: HSP90Summary: Oral Hsp90β inhibitor, novel, fully synthetic
- A4065 PF-04929113 (SNX-5422)Target: HSP90Summary: Hsp90 inhibitor,potent and selective
- A4068 SNX-21121 CitationSummary: Hsp90 inhibitor,ATP-competitve,potent and selective
- A8202 Abiraterone acetateTarget: Cytochrome P450 (CYP450)Summary: Cytochrome p450 17a1 inhibitor